Quick Answer
Stoke Therapeutics, Inc. reported Cash and Equivalents of $84.22 million for fiscal year 2025.
Stoke Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $84.22M | -34.2% |
| 2024 | $127.98M | -33.1% |
| 2023 | $191.44M | +68.6% |
| 2022 | $113.56M | -21.6% |
| 2021 | $144.90M | -49.6% |
| 2020 | $287.31M | +29.1% |
| 2019 | $222.47M | +111.1% |
| 2018 | $105.40M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $83.39M | -44.4% | -17.8% |
| June 30, 2025 | $101.47M | -47.6% | -63.1% |
| March 31, 2025 | $274.82M | +53.9% | +114.7% |
| December 31, 2024 | $127.98M | -33.1% | -14.7% |
| September 30, 2024 | $150.02M | -21.0% | -22.5% |
| June 30, 2024 | $193.48M | +0.7% | +8.3% |
| March 31, 2024 | $178.58M | -6.2% | -6.7% |
| December 31, 2023 | $191.44M | +68.6% | +0.8% |
- Stoke Therapeutics, Inc. showed a decrease of -34.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, Stoke Therapeutics, Inc.’s cash and equivalents has declined by 20.1% (from $105.40 million to $84.22 million).
- The most recent figure is from Stoke Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: